Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.
The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). The overall objective was to better understand and explore primary non response and loss of response to anti-TNF agents in IBD. The outcome of this workshop is presented into two parts. This first section addresses definitions, frequency and pharmacological aspects of anti-TNF therapy failure, including pharmacokinetics of anti-TNF monoclonal antibodies and immune and non-immune mediated clearance of anti-TNF mAbs. The second section concerns the biological roles of TNF and TNF antagonists, including mechanisms of action of anti-TNF agents, and discuss hypothesis regarding their failures and phenomenon of paradoxical inflammation, including the potential role of TNF independent inflammatory pathways.
Department of Gastroenterology, Hôpital Saint-Louis, APHP, Université Paris 7 Denis Diderot, France; Equipe Avenir INSERM U940, France. matthieu.allez@sls.aphp.fr
Matthieu
M
Allez
Konstantinos
K
Karmiris
Edouard
E
Louis
Gert
G
Van Assche
Shomron
S
Ben-Horin
Amir
A
Klein
Janneke
J
Van der Woude
Filip
F
Baert
Rami
R
Eliakim
Konstantinos
K
Katsanos
Jørn
J
Brynskov
Flavio
F
Steinwurz
Silvio
S
Danese
Severine
S
Vermeire
Jean-Luc
JL
Teillaud
Marc
M
Lémann
Yehuda
Y
Chowers
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000276:immunology; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology; D051379:Mice; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha